Sagimet Biosciences Inc.
SGMTNASDAQHealthcareBiotechnology
Previous close
$10.25
+$0.07 · +0.69%
SGMT company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
37
Expensive
Momentum
53
Neutral
Sentiment
44
Mixed
Risk resilience
24
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- David Happel
- Listed since
- Jul 14, 2023
- Employees
- 16
Market position
Day range
Current $10.25
52-week range
Current $10.25
- Open
- $10.18
- Previous close
- $10.18
- Volume
- 1.02M
- 0.61× average
- Average volume
- 1.68M
- Average daily volume
- Market cap
- 333.96M USD
- Beta
- 3.4
- Market reference 1
- 50-day average
- $7.8779
- +30.11% above average
- 200-day average
- $6.6956
- +53.09% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 156.54M USD
- P/E (TTM)
- -8.01×
- P/B (TTM)
- 2.13×
- P/S (TTM)
- 0×
- EV / EBITDA
- -3.07×
- Earnings yield
- -26.65%
- Free cash flow yield
- -23.84%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -45.82%
- Return on assets
- -43.82%
- Return on invested capital
- -51.04%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 22.82×
- Altman Z-score
- 26.04
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 2M USD | — | — |
| Gross profit | — | — | 2M USD | — | — |
| Research and development | 39.05M USD | 38.44M USD | 19.78M USD | 24.92M USD | 19.34M USD |
| Selling, general, and administrative | 17.84M USD | 16.01M USD | 12.96M USD | 6.14M USD | 4.38M USD |
| Operating expenses | 56.89M USD | 54.45M USD | 32.74M USD | 31.06M USD | 23.72M USD |
| Interest income | 5.85M USD | 8.89M USD | 2.86M USD | 553K USD | 26K USD |
| Depreciation and amortization | — | — | — | 130K USD | — |
| Operating income | −56.89M USD | −54.45M USD | −30.74M USD | −31.06M USD | −23.72M USD |
| Net income | −51.04M USD | −45.57M USD | −27.88M USD | −30.5M USD | −24.44M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 82%
- 9 beats, 2 misses, 0 met estimates
- Average EPS surprise
- +16.14%
- 11 comparable reports
- Latest EPS result
- -0.26
- Estimate -0.25 · Miss by 3.59%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$7.00
31.71% downsideRating distribution
7 ratingsRecent analyst actions
SGMT news
SGMT peers
ETFs holding SGMT
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM15.01M0.02%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI13.23M0.00%2.3T USD0.03%$378.24+0.44%
State Street SPDR S&P Biotech ETFXBI10.5M0.09%11.39B USD0.35%$165.73+1.44%
Vanguard Extended Market ETFVXF4.69M0.00%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB4.43M0.04%10.75B USD0.44%$213.56+1.29%
iShares Russell 2000 Growth ETFIWO4.39M0.03%15.16B USD0.24%$387.37+1.24%
Vanguard Russell 2000 ETFVTWO2.35M0.01%17.4B USD0.06%$121.25+0.74%
iShares Micro-Cap ETFIWC2.06M0.14%1.53B USD0.60%$198.39+1.10%iShares Russell 2000 ETFIWM- Market value
- 15.01M
- Weight
- 0.02%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 13.23M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
State Street SPDR S&P Biotech ETFXBI- Market value
- 10.5M
- Weight
- 0.09%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Extended Market ETFVXF- Market value
- 4.69M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 4.43M
- Weight
- 0.04%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
iShares Russell 2000 Growth ETFIWO- Market value
- 4.39M
- Weight
- 0.03%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
Vanguard Russell 2000 ETFVTWO- Market value
- 2.35M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
iShares Micro-Cap ETFIWC- Market value
- 2.06M
- Weight
- 0.14%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Continue in GoAI
Research SGMTresearch.disclaimer